Glutathione Precursor, N-Acetyl-Cysteine, Improves Mismatch Negativity in Schizophrenia Patients

Lavoie, Suzie, Murray, Micah M, Deppen, Patricia, Knyazeva, Maria G, Berk, Michael, Boulat, Olivier, Bovet, Pierre, Bush, Ashley I, Conus, Philippe, Copolov, David, Fornari, Eleonora, Meuli, Reto, Solida, Alessandra, Vianin, Pascal, Cuénod, Michel, Buclin, Thierry, Do, Kim Q·2008·Neuropsychopharmacology
DOI 10.1038/sj.npp.1301624

Cited by (370)

Items 201–300 of 370

  1. Future perspectives on the treatment of cognitive deficits and negative symptoms in schizophrenia
    DONALD C. GOFF · 2013 · World Psychiatry
  2. AMPA glutamate receptors mediate the antidepressant-like effects of N-acetylcysteine in the mouse tail suspension test
    Viviane M. Linck, Luciane Costa-Campos, Luísa K. Pilz, Cícero R.L. Garcia, Elaine Elisabetsky · 2012 · Behavioural Pharmacology
  3. Effects of memantine added to risperidone on the symptoms of schizophrenia: A randomized double-blind, placebo-controlled clinical trial
    Robabeh Mazinani, Somayeh Nejati, Mohammadreza Khodaei · 2016 · Psychiatry Research
  4. Preventing, treating, and predicting barbering: A fundamental role for biomarkers of oxidative stress in a mouse model of Trichotillomania
    Giovana de L. T. Vieira, Amy C. Lossie, Donald C. Lay Jr., John Scott Radcliffe, Joseph Paul Garner · 2017 · PLoS ONE
  5. Effects of acute N-acetylcysteine challenge on cortical glutathione and glutamate in schizophrenia: A pilot in vivo proton magnetic resonance spectroscopy study
    Ragy R. Girgis, Seth C. Baker, Xiangling Mao, Roberto B. Gil, Daniel C. Javitt, Joshua T. Kantrowitz, Meng Gu, Daniel M. Spielman, Najate Ojeil, Xiaoyan Xu et al. · 2019 · Psychiatry Research
  6. The distinction between temporal order and duration processing, and implications for schizophrenia
    Jennifer T. Coull, Anne Giersch · 2022 · Nature Reviews Psychology
  7. Learning-induced plasticity in human audition: Objects, time, and space
    Lucas Spierer, Marzia De Lucia E, Fosco Bernasconi, Jeremy Grivel, Nathalie M.-P. Bourquin, Stéphanie Clarke, Micah M. Murray · 2010 · Hearing Research
  8. Hippocampal glutamatergic/NMDA receptor functioning in bipolar disorder: A study combining mismatch negativity and proton magnetic resonance spectroscopy
    Kate M. Chitty, Jim Lagopoulos, Ian Bernard Hickie, Daniel Francis Hermens · 2015 · Psychiatry Research Neuroimaging
  9. Drugs Based on NMDAR Hypofunction Hypothesis in Schizophrenia
    Qiongqiong Wu, Jing Huang, Renrong Wu · 2021 · Frontiers in Neuroscience
  10. The neuroprotective effects of N-acetylcysteine in psychiatric and neurodegenerative disorders: From modulation of glutamatergic transmission to restoration of synaptic plasticity
    Suwarna Chakraborty, Shankaranarayana Rao, Sunil Jamuna Tripathi · 2025 · Neuropharmacology
  11. Potential Novel Therapies for Neurodevelopmental Diseases Targeting Oxidative Stress
    Alexandrina-Ștefania Curpăn, Alina-Costina Luca, Alin Stelian Ciobica · 2021 · Oxidative Medicine and Cellular Longevity
  12. Translating the Rosetta Stone of N-Acetylcysteine
    Olivia May Dean, Ashley Ian Bush, Michael Berk · 2012 · Biological Psychiatry
  13. Redox Dysregulation in Schizophrenia: Genetic Susceptibility and Pathophysiological Mechanisms
    K. Q. Do, P. Bovet, Jan-Harry Cabungcal, P. Conus, René Gysin, S. Lavoie, P. Steullet, Michel Cuénod · 2009 · Springer eBooks
  14. Neuroprotection in Schizophrenia and Its Therapeutic Implications
    Yong‐Ku Kim, Kyoung‐Sae Na · 2017 · Psychiatry Investigation
  15. Oxindole–curcumin hybrid compound enhances the transcription of γ-glutamylcysteine ligase
    Takanori Ikawa, Mina Sato, Kentaro Oh‐hashi, Kyoji Furuta, Yoko Hirata · 2021 · European Journal of Pharmacology
  16. Gene set enrichment analysis of pathophysiological pathways highlights oxidative stress in psychosis
    Giorgio Pistis, Javier Vázquez-Bourgón, Margot Fournier, Raoul Jenni, Martine Cleusix, Sergi Papiol, Sophie E. Smart, Antonio F. Pardiñas, James Walters, James Hunter MacCabe et al. · 2022 · Molecular Psychiatry
  17. Alpha7 nicotinic‐N‐methyl‐D‐aspartate hypothesis in the treatment of schizophrenia and beyond
    Maju Mathew Koola · 2020 · Human Psychopharmacology Clinical and Experimental
  18. Capitalizing on Extrasynaptic Glutamate Neurotransmission to Treat Antipsychotic-Resistant Symptoms in Schizophrenia
    John Harrison Krystal · 2008 · Biological Psychiatry
  19. Cerebral venous congestion alters brain metabolite profiles, impairing cognitive function
    Huimin Wei, Huimin Jiang, Yifan Zhou, Xuechun Xiao, Chen Zhou, Xunming Ji · 2023 · Journal of Cerebral Blood Flow & Metabolism
  20. Biomarkers in Psychosis: An Approach to Early Identification and Individualized Treatment
    Heline Mirzakhanian, Fiza Singh, Kristin S. Cadenhead · 2013 · Biomarkers in Medicine
  21. Involvement of the primate specific gene G72 in schizophrenia: From genetic studies to pathomechanisms
    Eva Drews, David-Marian Otte, Andreas Zimmer · 2012 · Neuroscience & Biobehavioral Reviews
  22. Mountain-Cultivated Ginseng Attenuates Phencyclidine-Induced Abnormal Behaviors in Mice by Positive Modulation of Glutathione in the Prefrontal Cortex of Mice
    The-Vinh Tran, Eun‐Joo Shin, Sung Kwon Ko, Yunsung Nam, Yoon Hee Chung, Ji Hoon Jeong, Choon‐Gon Jang, Seung-Yeol Nah, Kiyofumi Yamada, Toshitaka Nabeshima et al. · 2016 · Journal of Medicinal Food
  23. Validation of oxidative stress assay for schizophrenia
    Eunkyoung Kim, Zoe Keskey, Mijeong Kang, Christopher Kitchen, William E. Bentley, Shuo Chen, Deanna L. Kelly, Gregory Francis Payne · 2019 · Schizophrenia Research
  24. Current challenges and possible future developments in personalized psychiatry with an emphasis on psychotic disorders
    Аnastasia Levchenko, Timur Nurgaliev, Alexander A Kanapin, Anastasia A. Samsonova, Raul R. Gainetdinov · 2020 · Heliyon
  25. Handbook of neurochemistry and molecular neurobiology, schizophrenia
    Ábel Lajtha, Daniel C. Javitt, Joshua T. Kantrowitz · 2009 · Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B))
  26. The rise and fall of felbamate as a treatment for partial epilepsy – aplastic anemia and hepatic failure to blame?
    Karan B. Thakkar, Gauri Billa, Jay Rane, Hiren Chudasama, Sailendra Goswami, Rajen Shah · 2015 · Expert Review of Neurotherapeutics
  27. High dose N-acetyl cysteine improves inflammatory response and outcome in patients with COPD exacerbations
    Ahmed Mahmoud Abd El Hafiz, Lamia Mohamed El Wakeel, Hend Mohammed El Hady, Abd El Raheem Mourad · 2013 · Egyptian Journal of Chest Diseases and Tuberculosis
  28. Placebo-Controlled Augmentation Trials of the Antioxidant Nac in Schizophrenia: A Review
    Alexander T. Chen, John T. Chibnall, Henry A. Nasrallah · 2016 · Annals of Clinical Psychiatry
  29. The PPAR α Agonist Fenofibrate Reduces Prepulse Inhibition Disruption in a Neurodevelopmental Model of Schizophrenia
    Benjamin Rolland, Kévin Marche, Olivier Cottencin, Régis Bordet · 2012 · Schizophrenia Research and Treatment
  30. Pharmacotherapy of cognitive deficits in schizophrenia
    Lewis A. Opler, Alice A. Medalia, Mark G. Opler, Stephen M. Stahl · 2013 · CNS Spectrums
  31. Toward early estimation and treatment of addiction vulnerability: radial arm maze and N-acetyl cysteine before cocaine sensitization or nicotine self-administration in neonatal ventral hippocampal lesion rats
    Kalyan N. Rao, Alena M. Sentir, Eric A. Engleman, Richard L. Bell, Leslie A. Hulvershorn, Alan F. Breier, Robert Andrew Chambers · 2016 · Psychopharmacology
  32. Adolescent GBR12909 exposure induces oxidative stress, disrupts parvalbumin-positive interneurons, and leads to hyperactivity and impulsivity in adult mice
    Asma Khan, Loek A. W. de Jong, Mary E. Kamenski, Kerin K. Higa, Jacinta D. Lucero, Jared W. Young, M. Margarita Behrens, Susan B. Powell · 2016 · Neuroscience
  33. Neurocognitive effects of an omega-3 fatty acid and vitamins E+C in schizophrenia: A randomised controlled trial
    Håvard Bentsen, Nils Inge Landrø · 2017 · Prostaglandins Leukotrienes and Essential Fatty Acids
  34. Antipsychotic-minocycline-acetylcysteine combination for positive, cognitive, and negative symptoms of schizophrenia
    Maju Mathew Koola · 2019 · Asian Journal of Psychiatry
  35. Multimodal prevention of first psychotic episode through N‐acetyl‐ l ‐cysteine and integrated preventive psychological intervention in individuals clinically at high risk for psychosis: Protocol of a randomized, placebo‐controlled, parallel‐group trial
    Stefanie J. Schmidt, René Hurlemann, Johannes Schultz, Sven Wasserthal, Christian Kloss, Wolfgang Maier, Andreas Meyer‐Lindenberg, Martin Hellmich, Ana Muthesius, Tanja Pantel et al. · 2019 · Early Intervention in Psychiatry
  36. Oxidative stress and schizophrenia: A comparative cross‐sectional study of multiple oxidative markers in patients and their first‐degree relatives
    Eray Metin Güler, Ayşe Kurtulmuş, Ayşe Zehra Gül, Abdürrahim Koçyiğit, İsmet Kırpınar · 2021 · International Journal of Clinical Practice
  37. Recent Reports on Redox Stress-Induced Mitochondrial DNA Variations, Neuroglial Interactions, and NMDA Receptor System in Pathophysiology of Schizophrenia
    Narasimha Murthy Beeraka, Marco Ávila-Rodriguez, Gjumrakch Aliev · 2022 · Molecular Neurobiology
  38. Intervention dans la phase précoce des troubles psychotiques : objectifs et organisation du programme TIPP (Traitement et intervention dans la phase précoce des troubles psychotiques) à Lausanne
    P. Conus, Andrea Polari, C. Bonsack · 2010 · L information psychiatrique
  39. Investigating the role of glutathione in mismatch negativity: An insight into NMDA receptor disturbances in bipolar disorder
    Kate M. Chitty, Jim Lagopoulos, Ian Bernard Hickie, Daniel Francis Hermens · 2014 · Clinical Neurophysiology
  40. The inhibition of human T cell proliferation by the caspase inhibitor z-VAD-FMK is mediated through oxidative stress
    Tanuja Rajah, Sek C. Chow · 2014 · Toxicology and Applied Pharmacology
  41. N-acetylcysteine prevents increased amphetamine sensitivity in social isolation-reared mice
    Ana Paula Herrmann, Radharani Benvenutti, Luísa K. Pilz, Elaine Elisabetsky · 2014 · Schizophrenia Research
  42. Progressive Impairment of Mismatch Negativity Is Reflective of Underlying Pathophysiological Changes in Patients With First-Episode Psychosis
    Silvia Kyungjin Lho, Minah Kim, Jihye Park, Wu Jeong Hwang, Sun‐Young Moon, Sanghoon Oh, Jun Soo Kwon · 2020 · Frontiers in Psychiatry
  43. N-acetylcysteine modulates hallucinogenic 5-HT2A receptor agonist-mediated responses: Behavioral, molecular, and electrophysiological studies
    Mei-Yi Lee, Chun‐Cheng Chiang, Hong‐Yi Chiu, Ming‐Huan Chan, Hwei‐Hsien Chen · 2014 · Neuropharmacology
  44. Influence of dose and exposition time in the effectiveness of N-Acetyl-l-cysteine treatment in A549 human epithelial cells
    Paula Montero, Inés Roger, Cristina Estornut, Javier Milara, Julio Cortijo · 2023 · Heliyon
  45. Glutamate modulators for treatment of schizophrenia
    Naista Zhand, David G. Attwood, Philip D. Harvey · 2019 · Personalized Medicine in Psychiatry
  46. ENACT: a protocol for a randomised placebo-controlled trial investigating the efficacy and mechanisms of action of adjunctive N-acetylcysteine for first-episode psychosis
    Sue Cotton, M. Berk, Amity Watson, Stephen James Wood, Kelly Allott, Cali Bartholomeusz, Chiara C. Bortolasci, Ken R. Walder, Brian N. O'Donoghue, Olivia May Dean et al. · 2019 · Trials
  47. l-Cysteine
    Bilqees Sameem, Fazlullah Khan, Kamal Niaz · 2018 · Elsevier eBooks
  48. Transcranial direct current stimulation of prefrontal cortex: An auditory event-related potential and proton magnetic resonance spectroscopy study
    Lilly Knechtel, Ulrich Schall, Gavin J. Cooper, Saadallah A. Ramadan, Peter Stanwell, Todd A. D. Jolly, Renate Thienel · 2014 · Neurology Psychiatry and Brain Research
  49. Paying attention to MMN in schizophrenia
    Karlye A. M. Damaso, Patricia Therese Michie, Juanita Todd · 2015 · Brain Research
  50. Role of Novel Dietary Supplement N-acetyl Cysteine in Treating Negative Symptoms in Schizophrenia: A 6-Month Follow-up Study
    Hema Tharoor, Sindhu Mara, Subhashini Gopal · 2018 · Indian Journal of Psychological Medicine
  51. Overexpression of kynurenic acid and 3-hydroxyanthranilic acid after rat traumatic brain injury
    A. Mangas, M. Heredia, A. Riolobos, A. M. de la Fuente, J. Criado, J. Yajeya, M. Geffard, R. Coveñas · 2018 · European Journal of Histochemistry
  52. Recycling N-acetylcysteine: A review of evidence for adjunctive therapy in schizophrenia
    Robert J. Willborn, Colleen P. Hall, Matthew A. Fuller · 2019 · Mental Health Clinician
  53. Effect of single dose N-acetylcysteine administration on resting state functional connectivity in schizophrenia
    Grant McQueen, Aderlee Lay, John Lally, Anthony S. Gabay, Tracy Collier, David J. Lythgoe, Gareth J. Barker, James M. Stone, Philip K. McGuire, James Hunter MacCabe et al. · 2019 · Psychopharmacology
  54. An inverse relationship between plasma glutathione concentration and fasting glycemia in patients with coronary artery disease and concomitant type 2 diabetes: A pilot study
    Kamil Karolczak, Paweł Kubalczyk, Rafał Głowacki, Robert Pietruszyński, Cezary W. Watała · 2017 · Advances in Clinical and Experimental Medicine
  55. Ferroptosis in schizophrenia: Mechanisms and therapeutic potentials (Review)
    Shuang Lv, Chunxia Luo · 2024 · Molecular Medicine Reports
  56. Caenorhabditis elegans as a model system to study post-translational modifications of human transthyretin
    Andrea Henze, Thomas Homann, Isabelle Rohn, Michael Aschner, Christopher D. Link, Burkhard Kleuser, Florian J. Schweigert�, Tanja Schwerdtle, Julia Bornhorst · 2016 · Scientific Reports
  57. Connecting Neurobiological Features with Interregional Dysconnectivity in Social-Cognitive Impairments of Schizophrenia
    Florian W. Adraoui, Linda Douw, Gerard J.M. Martens, Dorien A. Maas · 2023 · International Journal of Molecular Sciences
  58. Effect of Tandospirone on Mismatch Negativity and Cognitive Performance in Schizophrenia
    Yuko Higuchi, Tomiki Sumiyoshi, Yasuhiro Kawasaki, Toru Ito, Tomonori Seo, Michio Suzuki · 2010 · Journal of Clinical Psychopharmacology
  59. Transcranial direct current stimulation of prefrontal cortex: An auditory event-related potential study in schizophrenia
    Lilly Knechtel, Renate Thienel, Gavin J. Cooper, Vanessa Case, Ulrich Schall · 2014 · Neurology Psychiatry and Brain Research
  60. Trace Amine-Associated Receptor 1 as a Target for the Development of New Antipsychotics: Current Status of Research and Future Directions
    Joshua T. Kantrowitz · 2021 · CNS Drugs
  61. Blood plasma proteomic modulation induced by olanzapine and risperidone in schizophrenia patients
    Sheila Garcia, Benilton S. Carvalho, Paul C. Guest, Johann Steiner, Daniel Martins‐de‐Souza · 2020 · Journal of Proteomics
  62. Redox Dysregulation and Oxidative Stress in Schizophrenia: Nutrigenetics as a Challenge in Psychiatric Disease Prevention
    Kim Q., Philippe Conus, Michel Cuénod · 2010 · Lifestyle Genomics
  63. Postmortem Brain Tissue for Drug Discovery in Psychiatric Research
    Suyeon Kim, Maree J. Webster · 2009 · Schizophrenia Bulletin
  64. Decreased Serum Sulphydryl Levels as a Sign of Increased Oxidative Stress in Generalized Anxiety Disorder
    Mehmet Kaya, Yasin Bez, İbrahim Fatih Karababa, Ali Emhan, Nurten Aksoy, Mahmut Bulut, Mehmet Güneş, Abdullah Atlı, Salih Selek · 2013 · Psychiatry Investigation
  65. Abnormal development of early auditory processing in 22q11.2 Deletion Syndrome
    Lucia-Manuela Cantonas, Miralena I. Tomescu, Marjan Biria, Reem Kais Jan, Maude Schneider, Stéphan Eliez, Tonia Anahi Rihs, Christoph Martin Michel · 2019 · Translational Psychiatry
  66. Glutamatergic Approaches to the Conceptualization and Treatment of Schizophrenia
    Joshua T. Kantrowitz, Daniel C. Javitt · 2009 · Springer eBooks
  67. Destruction of ERP responses to deviance in an auditory oddball paradigm in amyloid infusion mice with memory deficits
    Kim, Bowon, Shin, Jisu, Kim, YoungSoo, Choi, Jee Hyun · 2020 · PLOS ONE
  68. Biomarker innovations in precision psychiatry diagnostics and treatment strategies
    Martien J. Kas, Kim Q., Michael S. Sand, Rouba Kozak, Elizabeth M. Tunbridge, María A. Oquendo, Carol A. Tamminga, Nikolaos Koutsouleris, Gitte M. Knudsen, Brenda W.J.H. Penninx et al. · 2026 · European Neuropsychopharmacology
  69. Oxidative Stress in the Early Stage of Psychosis
    Antonio Ventriglio, Antonello Bellomo, Donato Favale, Iris Bonfitto, Giovanna Vitrani, Di Sabatino Dario, Edwige Cuozzo, Di Gioia Ilaria, Mauro Pettorruso, Giampaolo Perna et al. · 2021 · Current Topics in Medicinal Chemistry
  70. Stable solid dispersion of lurasidone hydrochloride with augmented physicochemical properties for the treatment of schizophrenia and bipolar disorder
    Vishwas P. Pardhi, Swaran J.S. Flora · 2020 · Biopharmaceutics & Drug Disposition
  71. Sources of the frontocentral mismatch negativity and P3a responses in schizophrenia patients and healthy comparison subjects
    Daisuke Koshiyama, Makoto Miyakoshi, Yash B. Joshi, Masaki Nakanishi, Kumiko Tanaka‐Koshiyama, Joyce Sprock, Gregory A. Light · 2021 · International Journal of Psychophysiology
  72. N-acetylcysteine improves EEG measures of auditory deviance detection and neural synchronization in schizophrenia: A randomized, controlled pilot study
    Yvonne S. Yang, Michael C. Davis, Jonathan K. Wynn, Gerhard Hellemann, Michael Foster Green, Stephen R. Marder · 2019 · Schizophrenia Research
  73. Contributions of Experimental Psychiatry to Research on the Psychosis Prodrome
    Mitja Bodatsch, Joachim Klosterkötter, Jörg Daumann · 2013 · Frontiers in Psychiatry
  74. Elucidating the glutamatergic processes underlying mismatch negativity deficits in early stage bipolar disorder and schizophrenia: A combined 1H-MRS and EEG study
    Manreena Kaur, Kate M. Chitty, Jim Lagopoulos, Ian Bernard Hickie, Shantel Leigh Duffy, Daniel Francis Hermens · 2019 · Journal of Psychiatric Research
  75. Bridging the gaps towards precision psychiatry: Mechanistic biomarkers for early detection and intervention
    Kim Q. · 2023 · Psychiatry Research
  76. Yi-Gan San Restores Behavioral Alterations and a Decrease of Brain Glutathione Level in a Mouse Model of Schizophrenia
    Manabu Makinodan, Takahira Yamauchi, Kouko Tatsumi, Hiroaki Okuda, Yoshinobu Noriyama, Miyuki Sadamatsu, Taishiro Kishimoto, Akio Wanaka · 2009 · Journal of brain disease
  77. Oxidative Stress in Psychiatric Disorders
    Lawrence K. Fung, Antonio Y. Hardan · 2018 · Springer eBooks
  78. Synaptic and cellular changes induced by the schizophrenia susceptibility gene G72 are rescued by N-acetylcysteine treatment
    Balázs Pósfai, Csaba Cserép, P Hegedüs, Eszter Szabadits, David M. Otte, A Zimmer, Masahiko Watanabe, Tamás F. Freund, Gábor Nyíri · 2016 · Translational Psychiatry
  79. MEGA-PRESS and PRESS measure oxidation of glutathione in a phantom
    Maiken K. Brix, Gerard Eric Dwyer, Alexander R. Craven, Renate Grüner, Ralph Noeske, Lars Ersland · 2019 · Magnetic Resonance Imaging
  80. Why mismatch negativity continues to hold potential in probing altered brain function in schizophrenia
    Juanita Todd, Dean F. Salisbury, Patricia Therese Michie · 2023 · Psychiatry and Clinical Neurosciences Reports
  81. N-Acetylcysteine and Metabotropic Glutamate Receptors: Implications for the Treatment of Schizophrenia: A Literature review
    Adam Daniel Zavodnick, Rizwan Ali · 2014 · Psychiatric Quarterly
  82. The coupling of low-level auditory dysfunction and oxidative stress in psychosis patients
    Eveline Geiser, Chrysa Retsa, Jean‐François Knebel, Carina Ferrari, Raoul Jenni, Margot Fournier, Luis Alameda, Philipp Baumann, Stéphanie Clarke, Philippe Conus et al. · 2017 · Schizophrenia Research
  83. N-Acetylcysteine versus arsenic poisoning: A mechanistic study of complexation by molecular spectroscopy and density functional theory
    Moumita Das, Keshav Kumar Singh, Eram Khan, Rajeev K. Sinha, Ranjan K. Singh, Poonam Tandon, Debraj Gangopadhyay · 2021 · Journal of Molecular Liquids
  84. Repurposed Drugs for the Treatment of Schizophrenia and Bipolar Disorders
    J. Malte Bumb, Frank Enning, F. Markus Leweke · 2013 · Current Topics in Medicinal Chemistry
  85. Oral acetylcysteine for neuropsychiatric disorders.
    Rebecca Racz, B. V. Sweet, P. Sohoni · 2015 · American Journal of Health-System Pharmacy
  86. The mismatch negativity (MMN): An introduction
    Risto Näätänen, Teija Kujala, Gregory A. Light · 2019 · Oxford University Press eBooks
  87. Effect of quetiapine on cognitive function in schizophrenia: a mismatch negativity potentials study
    Guozhen Yuan, Zhenhe Zhou, Jianjun Yao · 2009 · Acta Neuropsychiatrica
  88. Dysregulation of Glutathione Synthesis in Psychiatric Disorders
    Elżbieta Lorenc‐Koci · 2014 · Oxidative stress in applied basic research and clinical practice
  89. N-Acetylcysteine Mitigates Ketamine Neurotoxicity in Young Rats by Modulating ROS-Mediated Pyroptosis and Ferroptosis
    Hui Bai, Hui Chen, Shan Du, Di Qiu, Siyao Li, Tianwen Ma, Ruifeng Gao, Zhiheng Zhang · 2025 · Molecular Neurobiology
  90. Grant Report on D-Serine Augmentation of Neuroplasticity-Based Auditory Learning in Schizophrenia †
    Natalie de la Garrigue, Juliana Glasser, Pejman Sehatpour, Dan Vlad Iosifescu, Elisa C. Dias, Marlene Carlson, Constance B. Shope, Tarek M. Sobeih, Tse Hwei Choo, Melanie M. Wall et al. · 2020 · Journal of Psychiatry and Brain Science
  91. Intervention dans la phase précoce des troubles psychotiques : objectifs et organisation du programme TIPP (Traitement et intervention dans la phase précoce des troubles psychotiques) à Lausanne
    Philippe Conus, Andrea R. Polari, Charles Bonsack · 2010 · L information psychiatrique
  92. Serum free thiols in recently diagnosed patients with schizophrenia spectrum disorder: A potentially useful biomarker of oxidative stress
    Jenny Borkent, Magdalini Ioannou, Tessa S. Folkertsma, Klaas J. Wardenaar, Bartholomeus C. M. Haarman, Harry van Goor, Iris E. Sommer, Arno R. Bourgonje · 2023 · Psychiatry Research
  93. Towards an Integrated View of Early Molecular Changes Underlying Vulnerability to Social Stress in Psychosis
    Henry Barron, Sina Hafizi, Romina Mizrahi · 2017 · Modern trends in psychiatry
  94. Can N‑acetylcysteine, varenicline, or the combination prevent psychosis by enhancing mismatch negativity?
    Maju Mathew Koola · 2018 · Schizophrenia Research
  95. BODIPY-Hg2+ Complex: A Fluorescence “Turn-ON” Sensor for Cysteine Detection
    Monu Kumar, Garima Chaudhary, Amit Pratap Singh · 2020 · Analytical Sciences
  96. Making bloodwork work: the impact of sample collection, processing, and storage on plasma glutathione measurement, and implications for translation
    Kendall M. Coden, Duyen K. K. Nguyen, Roberta C. Moorhead, Beatriz E. Stix-Brunell, Joanna N. Baker, Karen J. Parker, Joseph Paul Garner · 2024 · Translational Psychiatry
  97. Reduction of oxidative stress improves insulin signaling in cardiac tissue of obese mice
    Matheus Scarpatto Rodrigues, Bruno Luiz da Silva Pieri, Gustavo de Bem Silveira, Rubya Pereira Zaccaron, Ligia Milanez Venturini, Vitor Hugo Comin, Karine Damian Luiz, Paulo César Lock Silveira · 2020 · Einstein (São Paulo)
  98. Alcohol use in bipolar disorder: A neurobiological model to help predict susceptibility, select treatments and attenuate cortical insult
    Kate M. Chitty, Jim Lagopoulos, Ian Bernard Hickie, Daniel Francis Hermens · 2015 · Neuroscience & Biobehavioral Reviews
  99. Regarding “N-Acetyl Cysteine as a Glutathione Precursor for Schizophrenia—A Double-Blind, Randomized, Placebo-Controlled Trial”
    Kenji Hashimoto · 2008 · Biological Psychiatry
  100. Novel drug treatments for schizophrenia
    Joseph T. Coyle, Steven M. Paul · 2026 · Nature Reviews Drug Discovery